Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped...
Pregnancy
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti®...
Cedar Gate Data Finds Nearly 60% of New Mothers Miss Essential Postpartum Follow-Up Care
Nationwide analysis of commercially insured members shows missed appointments far exceed prior estimates, highlighting urgent gaps in maternal health accessGREENWICH,...
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the...
Health Canada Authorizes bioLytical’s iStatis Syphilis Test, Boosting Rapid Response to Rising Infections in Canada
Now authorized for professional use in Canada, the iStatis Syphilis Antibody Test offers a fast, accurate, and portable solution to...
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US...
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Women’s Health Diagnostics Market Hits $14.6 Billion–Kalorama Information Report Reveals Key Growth Drivers to 2030
Comprehensive analysis reveals emerging opportunities in imaging, molecular diagnostics, and AI-driven tools as women's health takes center stage in global...
Flo for Perimenopause is Launching to Empower the 1 Billion+ Women Who Experience Perimenopause Without the Support They Deserve
A new feature from Flo Health aims to improve health literacy during a women's life stage that has been underserved...
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together...
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Ultrasound AI Partners with MedLatam to Expand Access to Life-Saving AI-Powered Prenatal Diagnostics Across Brazil
The company builds upon its ANVISA approval, launching its patented software in one of the world's largest and most at-risk...
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage...
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase...
INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare...
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts,...
SlimJaro Botanical Approaches Gain Interest in 2025 for Inflammation-Related Metabolic Wellness
A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns....
Carrot Unveils New Program to Redefine Metabolic-Fertility Care
Sprints Program will Combat Leading Causes of Infertility, Reduce IVF Cycles, and Help Achieve Healthier Pregnancies – Faster – with...
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE)...